---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-118988"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:47:35.184955+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amarin Q3 net revenue $42.3M (-36% YoY); European revenue grows, U.S. declines on generic competition

## Summary
- Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.
- European net product revenue $4.3M (up from $0.8M); VAZKEPA sales grew 19% sequentially in Spain and UK.
- Net loss $25.1M ($0.06/share) vs $19.3M loss ($0.05); non-GAAP adjusted net loss $20.4M ($0.05).
- Cash and investments $305.7M, flat QoQ; reaffirms cash adequate for foreseeable future.
- Company committed to maintaining public listing; exploring paths to resolve issue. Virtual Analyst Day Nov 14.

## SEC filing metadata
- accession: 0000950170-24-118988
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000095017024118988/0000950170-24-118988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000095017024118988/amrn-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-118988
- JSON: https://secwatch.observer/filing/0000950170-24-118988.json
- Plain text: https://secwatch.observer/filing/0000950170-24-118988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.